<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16804">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02121509</url>
  </required_header>
  <id_info>
    <org_study_id>1288.10</org_study_id>
    <secondary_id>2013-005143-85</secondary_id>
    <nct_id>NCT02121509</nct_id>
  </id_info>
  <brief_title>Bioequivalence of a Low, Fixed Dose Combination Tablet of Linagliptin/Metformin Extended Release in Healthy Subjects</brief_title>
  <official_title>Bioequivalence of a Fixed Dose Combination Tablet of Linagliptin/Metformin Extended Release (2.5 mg/750 mg) Compared With the Free Combination of Linagliptin and Metformin Extended Release Tablets in Healthy Subjects (an Open-label, Randomised, Single Dose, Two-way Crossover Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to demonstrate bioequivalence of a newly developed fixed dose
      combination (FDC) tablet containing linagliptin and metformin extended release compared to
      the free combination of linagliptin and metformin extended release.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 hours (AUC0-72)</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum measured concentration of linagliptin in plasma (Cmax)</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve of metformin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of metformin in plasma</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf)</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf of metformin in plasma</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>FDC first, fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fasted condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single tablets first, fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fasted condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FDC first, fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fed condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single tablets first, fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fed condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <description>1 x Linagliptin tablet</description>
    <arm_group_label>FDC first, fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <description>1 x Linagliptin tablet</description>
    <arm_group_label>Single tablets first, fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin/Metformin ER FDC</intervention_name>
    <description>2 x Linagliptin/Metformin ER FDC tablet</description>
    <arm_group_label>Single tablets first, fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <description>1 x Linagliptin tablet</description>
    <arm_group_label>FDC first, fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin/Metformin ER FDC</intervention_name>
    <description>2 x Linagliptin/Metformin ER FDC tablet</description>
    <arm_group_label>FDC first, fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin ER</intervention_name>
    <description>3 x Metformin ER tablets</description>
    <arm_group_label>FDC first, fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin ER</intervention_name>
    <description>3 x Metformin ER tablets</description>
    <arm_group_label>Single tablets first, fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin ER</intervention_name>
    <description>3 x Metformin ER tablets</description>
    <arm_group_label>FDC first, fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin/Metformin ER FDC</intervention_name>
    <description>2 x Linagliptin/Metformin ER FDC tablet</description>
    <arm_group_label>Single tablets first, fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <description>1 x Linagliptin tablet</description>
    <arm_group_label>Single tablets first, fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin/Metformin ER FDC</intervention_name>
    <description>2 x Linagliptin/Metformin ER FDC tablet</description>
    <arm_group_label>FDC first, fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin ER</intervention_name>
    <description>3 x Metformin ER tablets</description>
    <arm_group_label>Single tablets first, fasted</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        - Healthy male or female subjects

        Exclusion criteria:

        - Any relevant deviation from healthy condition
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>1288.10.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ingelheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>April 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>BI 1356</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
